Stocksigma LogoStocksigma Logo

Goldline Pharmaceutical Confirms Nil Deviation in IPO Proceeds Utilization for Sep'26

Goldline Pharmaceutical Limited reported zero deviation or variation in the utilization of its IPO proceeds for the half-year ended 30th Sep'26

Goldline Pharmaceutical Confirms Nil Deviation in IPO Proceeds Utilization for Sep'26

Goldline Pharmaceutical Ltd 路 Others (Uncategorized) 路 15 Nov 2026, 1:26 am

Goldline Pharmaceutical Confirms Nil Deviation in IPO Proceeds Utilization for Sep'26 Goldline Pharmaceutical Limited reported zero deviation or variation in the utilization of its IPO proceeds for the half-year ended 30th Sep'26. The company raised gross proceeds of INR 1,161.00 Lakhs via an SME IPO on 19th May'26, netting INR 1,006.00 Lakhs. The entire net proceeds were fully utilized per stated prospectus objectives, deploying INR 835.45 Lakhs toward repayment of outstanding borrowings and INR 170.55 Lakhs for general corporate purposes. Both the Audit Committee and statutory auditors confirmed full compliance with no deviations.

Original exchange filing (PDF)

More announcements from Goldline Pharmaceutical Ltd

All Goldline Pharmaceutical Ltd announcements